A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research

Laccetti, Andrew L.; Morris, Michael J.

doi:10.2147/ott.s242921

Cited by 10 publications

(5 citation statements)

References 92 publications

(131 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Enzalutamide was the first second-generation AR antagonist approved by the FDA, and is now approved in combination with ADT for the treatment of castration resistant PCa, irrespective of the presence of metastases, pre-and post-chemotherapy metastatic CRPC (mCPC), non-metastatic CRPC (nmCPRC), and as first-line therapy in mCSPC (30). There is an increasing number of studies assessing the efficacy of enzalutamide in combination with current standard of care RT treatments.…”

Section: Discussionmentioning

confidence: 99%

“…Enzalutamide was the first second-generation AR antagonist approved by the Food and Drug Administration and is now approved in combination with ADT for the treatment of castration resistant PCa, irrespective of the presence of metastases, pre- and postchemotherapy metastatic CRPC (mCPC), nonmetastatic CRPC (nmCPRC), and as first-line therapy in mCSPC. 30 There is an increasing number of studies assessing the efficacy of enzalutamide in combination with current standard of care RT treatments. For example, Kaplan et al demonstrated effectiveness of enzalutamide monotherapy as a possible replacement for ADT in patients with intermediate PCa undergoing radiation therapy, using PSA response as a primary end point.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial

Shee

Calle

Chang

et al. 2022

Advances in Radiation Oncology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial

Shee

Calle

Chang

et al. 2022

Advances in Radiation Oncology

View full text Add to dashboard Cite

“…In addition, enzalutamide has also been shown to decrease proliferation and increase PCa cell death. It results in tumour regression in castration-resistant xenograft models, and was reported to show persistent in vitro activity in the setting of AR splice variants such as AR-V7 [ 27 ].…”

Section: Review Outcomesmentioning

confidence: 99%

Novel hormonal therapies in the management of advanced prostate cancer: extrapolating Asian findings to Southeast Asia

et al. 2023

View full text Add to dashboard Cite

There is a paucity of information on the use of novel hormonal agents in Southeast Asian patients. We reviewed the clinical roles of novel hormonal therapy (NHT), namely abiraterone acetate (AA), enzalutamide, apalutamide and darolutamide, in the management of advanced prostate cancer, and data on its use in Asian patients, in order to extrapolate these findings to the Southeast Asian patient population. There are some differences in the molecular features between the NHTs, which influenced their respective permeabilities through the blood–brain barrier. The Asian sub-analyses of the landmark studies of each NHT were limited. The primary endpoints of the Asian sub-analyses generally reflect the efficacy outcomes of the respective landmark study. Hypertension, fatigue, musculoskeletal disorders, rash, and hot flushes were among the common toxicities observed in Asian patients. Real-world data on AA in the Asian setting is favourable, but data is limited for enzalutamide, apalutamide and darolutamide. Based on the sub-analyses and real-world data, the efficacy and safety of NHTs in the Asian patients showed a similar trend to the respective landmark studies. The lack of clinical trials in the Southeast Asian region hampers the ability to make a robust conclusion on any specific efficacy or safety differences that may be present; clinicians must assume that the broader Asian sub-analyses and real-world data reflects Southeast Asian patients' outcomes.

show abstract

“…Besides these agents, other radiopharmaceuticals and immunotherapies also serve as effective therapeutic options for mCRPC treatment [6]. Previously, mCSPC was managed with ADT, mostly in combination with androgen receptor (AR) antagonists like bicalutamide and flutamide [7]. However, no benefit in overall survival (OS) could be achieved with such therapy, and CSPC inevitably progressed to CRPC [7].…”

Section: Introductionmentioning

confidence: 99%

“…Previously, mCSPC was managed with ADT, mostly in combination with androgen receptor (AR) antagonists like bicalutamide and flutamide [7]. However, no benefit in overall survival (OS) could be achieved with such therapy, and CSPC inevitably progressed to CRPC [7]. Based on recent clinical data, ADT combined with upfront therapies, such as enzalutamide, apalutamide, and abiraterone acetate, has been approved by the US Food and Drug Administration (FDA) for mCSPC, in addition to CRPC [8].…”

Section: Introductionmentioning

confidence: 99%

Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus

Desai¹,

Vaid

Biswas

et al. 2022

Oncol Ther

View full text Add to dashboard Cite

Introduction: With the availability of an increasing number of therapeutic options for advanced prostate cancer (APC), optimal sequencing and combination of therapies have emerged to be the areas of challenges. In the Indian context, there is a dearth of consensus recommendations to guide clinicians regarding optimal sequencing of therapy in APC management. A Delphi-based consensus regarding optimal therapy sequencing in APC management was developed by an expert panel of medical oncologists from across India.Methods: An expert scientific committee of 11 medical oncologists and an expert panel of 53 medical oncologists from India constituted the panel for the Delphi consensus. In the first phase, a questionnaire with 41 clinical statements was developed in several critical controversial areas in APC treatment. In the second phase, 29 clinical statements were reworked and sent to eight experts to obtain their opinions on best practices. The consensus ratings were based on a 9-point Likert scale. Based on the overall response, statements with a mean score of C 7 with 1 outlier were considered as ''consensus.'' Results: Degarelix was the preferred androgen deprivation therapy (ADT). While ADT plus

show abstract

A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research

Cited by 10 publications

References 92 publications

Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial

Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial

Novel hormonal therapies in the management of advanced prostate cancer: extrapolating Asian findings to Southeast Asia

Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus

Contact Info

Product

Resources

About